ONCOLOGY Staff

Karen Kehl shares her decade-long journey with multiple myeloma, discussing treatment options and the impact of bispecific antibodies like talquetamab with Binod Dhakal, MD.

Experts at City of Hope explore innovative immunotherapy strategies for non-small cell lung cancer, highlighting efficacy and toxicity management in treatment.

Two teams of lymphoma experts engage in a face-off competition, showcasing real-world updates, patient cases, and use of ASCT or CAR T-cell therapy.

An expert discusses the vital role of comprehensive genomic profiling in personalizing treatment for non-small cell lung cancer, enhancing patient outcomes.

Read an expert-led article on the latest advancements in TROP2-targeted antibody-drug conjugates for treating triple-negative breast cancer and improving patient outcomes.

New therapies for hepatobiliary cancers show promise, expanding treatment options for patients with advanced disease and challenging conditions.

Recent advancements in multiple myeloma treatment highlight the efficacy of daratumumab combined with VRd, showcasing improved outcomes and tolerability.

Experts discuss evolving therapies for EGFR-mutated metastatic NSCLC, comparing combination regimens and their impact on patient outcomes.

Explore the latest advancements in c-Met-targeted therapies for NSCLC, including optimal testing strategies and management of adverse events.

Experts discussed teclistamab's efficacy in multiple myeloma, highlighting real-world data and treatment protocols.

Cilta-cel shows promising long-term efficacy in treating relapsed/refractory multiple myeloma, with significant survival rates and manageable safety profiles.

Experts discussed talquetamab's unique mechanism and favorable patient outcomes in relapsed/refractory multiple myeloma.

Experts debate cutting-edge multiple myeloma treatments, exploring pressing data, the most prominent news, and patient cases.

Oncologists explore the considerations of mirvetuximab soravtansine treatment in platinum-resistant ovarian cancer, highlighting its efficacy and the management of ocular AEs.

Innovative oncolytic virus therapies transform advanced melanoma treatment, enhance patient outcomes, and overcome resistance to traditional immunotherapies.

Explore innovative strategies and emerging therapies transforming small cell lung cancer treatment, enhancing patient outcomes and survival rates.

A proactive regimen reduces dermatologic AEs in patients with NSCLC who were treated with amivantamab and lazertinib, enhancing treatment adherence.

Experts analyze the evolving landscape of melanoma treatment, highlighting key clinical trials and strategies for optimizing patient outcomes.

Experts discussed diagnosing and treating epithelioid sarcoma, emphasizing the importance of clinical history and the role of multiple multidisciplinary clinicians in care.

Explore the latest advancements in pancreatic cancer treatment, focusing on genetic mutations, targeted therapies, and emerging clinical strategies.

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

Discover the latest advancements in metastatic castration-resistant prostate cancer care, including personalized treatment strategies and emerging therapies.

Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.

Experts discuss shifting preferences in EGFR-mutated NSCLC treatments, highlighting new survival data from the FLAURA2 and MARIPOSA trials shared at ELCC 2025.

Experts discuss innovative treatments for extensive-stage small cell lung cancer, highlighting tarlatamab's potential and management of adverse effects.

Read about various aspects of career trajectories in oncology from the perspective of established clinicians, new attendings, and those waiting to sit for their medical board exams.

Prostate-specific membrane antigen PET imaging has completely altered the landscape of prostate cancer detection and management. Read as several experts discuss the trajectory and growth of these agents.

Decipher Prostate, Oncotype DX, and Prolaris are 3 gene expression testing options for patients with prostate cancers. Read as experts discuss them.

"The data, even in fast progressors and within 6 months of endocrine therapy, [show it] is working," stated Monica Khunger Malhotra, MD.

Care for patients with chronic lymphocytic leukemia continues to evolve via novel targeted therapies. Here are 3 things every cancer care specialist should know about treating CLL.